在接受免疫治疗的癌症患者中,肥胖对生存的保护作用在控制癌症类型、体重下降和骨骼肌减少后消失
该研究为前瞻性队列的二次分析,纳入接受免疫检查点抑制剂治疗的黑色素瘤(n=411)和非小细胞肺癌(NSCLC,n=389)连续患者。单变量分析中超重/肥胖(BMI≥25 kg/m2)与更长生存相关(p<0.01),但仅见于NSCLC(p<0.01),黑色素瘤中不存在。控制体重下降和CT定义的骨骼肌质量后,所谓「肥胖悖论」消失。
要点
- 单变量分析中超重/肥胖(BMI≥25 kg/m2)与更长生存相关(p<0.01),但该效应仅见于NSCLC(p<0.01),黑色素瘤中不存在。
- 各BMI类别患者中均观察到体重下降和骨骼肌质量减少;体重下降在多变量分析中与两种肿瘤的更短生存相关(p<0.01)。
- 在NSCLC中,纳入体重下降后BMI失去显著性(p=0.13);进一步调整CT定义的骨骼肌质量后,体重下降对两种肿瘤仍显著(p<0.01),骨骼肌减少仅与NSCLC更短生存相关(p=0.02)。
核心结论
- 所谓「肥胖悖论」,即高BMI与更长生存的反直觉关联,在控制癌症类型及耗竭表现(体重下降和骨骼肌质量减少)等混杂因素后消失。
研究设计与样本
- 前瞻性队列的二次分析,纳入常规诊疗中接受免疫检查点抑制剂治疗的连续患者,包括黑色素瘤(n=411)和非小细胞肺癌(n=389)。
主要发现
- 整个人群单变量分析中,超重/肥胖(BMI≥25 kg/m2)与更长生存相关(p<0.01),但该效应仅限于NSCLC(p<0.01),黑色素瘤中不存在。
- 所有BMI类别患者中均观察到体重下降和骨骼肌质量减少;体重下降在多变量分析中与两种肿瘤的更短生存相关(p<0.01)。
- 在NSCLC中,纳入体重下降后BMI失去显著性(p=0.13);进一步调整CT定义的骨骼肌质量后,体重下降对两种肿瘤仍显著(p<0.01),骨骼肌减少仅与NSCLC更短生存相关(p=0.02)。
- 将生物标志物(乳酸脱氢酶、白蛋白和衍生中性粒细胞与淋巴细胞比值)加入多变量模型后,体重下降仍保持显著性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Association of high body mass index (BMI) with longer survival has been reported in patients on immune checkpoint inhibitors (ICIs), but results are inconsistent. This 'obesity paradox' is potentially confounded by the effects of BMI change over time and of skeletal muscle depletion. METHODS: We conducted a secondary analysis of a prospective cohort, including consecutive patients receiving ICI treatment for melanoma (n = 411) and non-small cell lung cancer (NSCLC) (n = 389) in routine care. RESULTS: In the univariable analysis of the entire population, overweight/obesity (BMI ≥ 25 kg/m2) was associated with longer survival (p < 0.01); however, this effect was limited to NSCLC (p < 0.01) and was absent in melanoma. Weight loss (WL) and reduced skeletal muscle mass were observed in patients within all BMI categories. WL was associated with shorter survival in multivariable analysis in both tumour sites (p < 0.01), and for NSCLC, BMI lost significance when WL was included (p = 0.13). In models further adjusted for CT-defined skeletal muscle mass, WL retained significance for both tumour types (p < 0.01), and reduced skeletal muscle only for NSCLC (p = 0.02) was associated with shorter survival. WL retained significance when biomarkers (lactate dehydrogenase enzyme, albumin and derived neutrophil to lymphocyte ratio) were added to the multivariable model. CONCLUSIONS: The so-called 'obesity paradox', counterintuitive association between high BMI and longer survival, vanished when controlling for confounders, such as type of cancer, and manifestations of depletion (WL and reduced skeletal muscle mass).
引用
- Antoun S, Lanoy E, Ammari S, et al. Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. Eur J Cancer. 2022. PMID: 36403367. doi:10.1016/j.ejca.2022.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。